Update on Certis Europe

RNS Number : 1687M

Eden Research plc

13 September 2012

 



EDEN RESEARCH PLC

("Eden" or "Company")

Update on Certis Europe

Eden Research plc, the agrochemical and encapsulation development company, announces that it is expanding its collaborative efforts with Certis Europe BV ("Certis") to investigate additional product applications, including using Eden's proprietary encapsulation technology with an existing agrochemical.

In addition, Eden has agreed to extend the term of the existing option agreement that it has with Certis for its nematode product to 31 March 2013 and, at the same time, restrict the territory to Europe only.

Clive Newitt, Managing Director of Eden said, "We are pleased to be building on the relationship that we have with Certis and are excited at the prospect of being able to investigate our unique encapsulation technologies in new product areas."

Eden Research plc	www.edenresearch.com
Clive Newitt, Managing Director	Tel: [phone]
Alex Abrey, Chief Financial Officer
Zeus Capital Limited
Ross Andrews, Andrew Jones	Tel: [phone]
John Goold (Institutional Sales)	Tel: [phone]
Walbrook PR Ltd	Tel: [phone]
Paul McManus (Media Relations)	Mob: [phone] or [e-mail]
Paul Cornelius (Investor Relations)	Mob: [phone] or [e-mail]

Notes:

Eden is an early stage revenue company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions to the global agrochemicals industry, the animal health industry, and consumer products.

Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with hydrophobic compounds both natural and synthetic. The technology uses yeast cells to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetic and pharmaceutical industries.

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

With leading consultants in their respective fields, the Company is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.

The Company has a number of patents and has a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £12m in developing and protecting its intellectual property. Revenues earned by the Company have been modest (2010: £172,000; 2011: £91,000) whilst the Company has concentrated on securing patent protection for its intellectual property, identifying suitable industrial partners and entering into licence agreements.

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.

For more information about Eden, please visit www.edenresearch.com 

 

END

 

 

MSCLJMFTMBABMTT